公开(公告)号：US20220305081A1

公开(公告)日：2022-09-29

申请号：US17618922

申请日：2020-06-23

Applicant: AMGEN INC.

Inventor： Ruozhen HU ,  Paolo MANZANILLO ,  Wenjun OUYANG

IPC: A61K38/17 ,  A61P35/00 ,  A61K47/02

Abstract: Provided herein are methods of treating a subject with a tumor or cancer. In exemplary embodiments, the method comprises increasing an immune response against the tumor or cancer in the subject or increasing effector activity or reducing suppressive activity of T-cells in the subject. In exemplary embodiments, the method comprises administering to the subject a SIRPγ binder, e.g., SIRPγ inhibitor, in an amount effective to treat the tumor or cancer in the subject.

公开(公告)号：US20230040604A1

公开(公告)日：2023-02-09

申请号：US17786375

申请日：2020-12-17

Applicant: AMGEN INC.

Inventor： Ashutosh CHAUDHRY ,  Wenjun OUYANG

IPC: C07K14/55 ,  C07K16/28 ,  C07K14/525 ,  C12N15/62 ,  C12N5/0783 ,  A61P37/06 ,  A61P37/04 ,  C12N15/85 ,  A61K47/64

Abstract: Provided herein are combinations of an IL-2 molecule or mutein and a TNFR agonist, and complexes comprising IL-2/TNFR agonist molecules, such as Fc-bound IL-2/TNFR agonist molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20210301020A1

公开(公告)日：2021-09-30

申请号：US17262339

申请日：2019-07-17

Applicant: AMGEN INC.

Inventor： Xin YU ,  Wenjun OUYANG ,  Chi-Ming Kevin LI ,  Jackson Graeme EGEN ,  Oh Kyu YOON ,  Ian Halsey DRIVER ,  Shunsuke TAKENAKA ,  Christy Ann THOMSON ,  Hongyu WANG

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.